title: Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor.
authors: Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands.
authors: Justine L
authors: JL
authors: Kuiper
authors: Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands.
authors: Merle I
authors: MI
authors: Ronden
authors: Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands.
authors: Annemarie
authors: A
authors: Becker
authors: Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
authors: Daniëlle A M
authors: DA
authors: Heideman
authors: Department of Pulmonary Diseases, Flevo Hospital, Almere, The Netherlands.
authors: Peter
authors: P
authors: van Hengel
authors: Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
authors: Bauke
authors: B
authors: Ylstra
authors: Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
authors: Erik
authors: E
authors: Thunnissen
authors: Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands Department of Pulmonary Diseases, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
authors: Egbert F
authors: EF
authors: Smit
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics*; D001706:Biopsy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000201:enzymology / Q000235:genetics / Q000473:pathology*; D004252:DNA Mutational Analysis; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics* / Q000378:metabolism; D000069347:Erlotinib Hydrochloride; D017809:Fatal Outcome; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D009154:Mutation; D010641:Phenotype; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: CANCER; LUNG CANCER; ONCOLOGY